Therapeutic Areas Driving Clinical Trial Growth Show Where AI Will Face the Next Bottlenecks

IQVIA’s analysis of therapeutic areas driving clinical trial growth matters because it identifies where innovation pressure is accumulating. The fastest-growing areas are often the ones with the hardest operational problems: more patients to recruit, more endpoints to manage, and more data to interpret.

That makes the piece relevant to healthcare AI even though it is not about a single model. AI adoption in trials tends to follow the complexity curve. Where studies are large, heterogeneous, and data-heavy, AI can add value in eligibility screening, site selection, monitoring, and evidence synthesis.

But the growth of trials also exposes the limits of current tools. More activity does not automatically mean more automation; it can also mean more fragmentation, more regulatory scrutiny, and more demand for human oversight. The therapeutic areas with the most momentum may be exactly where AI faces the strictest validation requirements.

The strategic takeaway is simple: AI vendors and sponsors should not think of clinical development as one market. It is a set of distinct bottlenecks shaped by disease area, trial design, and data maturity. The winners will be those that target operational pain points with enough specificity to show measurable value.